Commercial Strategy And LaunchCorMedix is gearing up for a strategic commercial launch of DefenCath, targeting both inpatient and outpatient settings, with clear timelines and confirmed interest from healthcare providers.
Pricing And ReimbursementWith DefenCath's list price set at $249.99 per 3mL vial and eligibility for reimbursement, CorMedix may see a favorable financial impact, enhancing the stock's attractiveness.
Product Approval And Market PotentialDefenCath received FDA approval and is recognized for its potential to significantly reduce catheter-related bloodstream infections in hemodialysis patients, which may lead to increased demand and market penetration.